12.07.2015 Views

Bilaga W1404-2.2.pdf - LIF

Bilaga W1404-2.2.pdf - LIF

Bilaga W1404-2.2.pdf - LIF

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Uttalad inflammationToradol 30 mg/mL.Ge 0,5 mL bolus iv, kan upprepas en gång efter 30 minuter.Dynastat vid blödningsrisk 40 mg iv.Vid svikt av konventionell terapiKetalar 10, 50 mg/mL.Ge 5 mg bolus, kan upprepas, psykotropa biverkningarbegränsar.Referenser1. Haugen DF, Hjermstad MJ, et al. Assessment and classification of cancerbreakthrough pain: A systematic literature review. Pain 2010.2. Lundstrom S, Gyllenhammar E, et al. Together we can: experiencesfrom 7 years of cross-sectional studies in a Swedish palliative careclinical research network. Palliat Med 2010;24(3):261–6.3. Kujath K, Hermann KG, et al. Severe disease activity and complicationsof immunosuppressive therapy: a challenge for acute hospital-based rehabilitationin rheumatology. J Rheumatol 2009;36(8):1618–25.4. Casserly IP. Interventional management of critical limb ischemia inrenal patients. Adv Chronic Kidney Dis 2008;15(4):384–95.5. Woolf CJ, Max MB. Mechanism-based pain diagnosis: issues for analgesicdrug development. Anesthesiology 2001;95(1):241–9.6. Davis MP, Walsh D, et al. Controversies in pharmacotherapy of painmanagement. Lancet Oncol 2005;6(9):696–704.7. Bannwarth B. Irrelevance of the WHO analgesic ladder for managingrheumatic pain. Joint Bone Spine 2010;77(1):1–3.8. Strang P. Cancerrelaterad smärta, 2003.9. Geber C, Baumgartner U, et al. Revised definition of neuropathic painand its grading system: an open case series illustrating its use in clinicalpractice. Am J Med 2009;122(Suppl 10):3–12.10. Moryl N, Coyle N, et al. Managing an acute pain crisis in a patient withadvanced cancer: this is as much of a crisis as a code. JAMA 2008;299(12):1457–67.11. Duggan ST, Scott LJ. Intravenous paracetamol (acetaminophen).Drugs 2009;69(1):101–13.12. Tasmacioglu B, Aydinli I, et al. Effect of intravenous administration ofparacetamol on morphine consumption in cancer pain control. SupportCare Cancer 2009;17(12):1475–81.13. Israel FJ, Parker G, et al. Lack of benefit from paracetamol (acetaminophen)for palliative cancer patients requiring high-dose strong opioids:a randomized, double-blind, placebo-controlled, crossover trial. JPain Symptom Manage 2010;39(3):548–54.14. Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors,and lessons from the clinic. FASEB J 2004;18(7):790–80415. Antman EM, Bennett JS, et al. Use of nonsteroidal antiinflammatorydrugs: an update for clinicians: a scientific statement from the AmericanHeart Association. Circulation 2007;115(12):1634–42.16. Zemmel MH. The role of COX-2 inhibitors in the perioperative setting:efficacy and safety--a systematic review.” AANA J 2006;74(1):49–60.17. Lloyd R, Derry S, et al. Intravenous or intramuscular parecoxib foracute postoperative pain in adults. Cochrane Database Syst Rev2009;(2):CD004771.18. Sinha VR, Kumar RV, et al. Ketorolac tromethamine formulations: anoverview. Expert Opin Drug Deliv 2009;6(9):961–75.19. Legge J, Ball N, et al. The potential role of ketamine in hospice analgesia:a literature review. Consult Pharm 2006;21(1):51–7.20. Stefanczyk-Sapieha L, Oneschuk D, et al. Intravenous ketamine ”burst”for refractory depression in a patient with advanced cancer. J PalliatMed 2008;11(9):1268–71.21. Hudetz JA, Patterson KM, et al. Ketamine attenuates delirium aftercardiac surgery with cardiopulmonary bypass. J Cardiothorac VascAnesth 2009;23(5):651–7.22. Mercadante S, Villari P, et al. Pamidronate in incident pain due to bonemetastases. J Pain Symptom Manage 2001;22(2):630–1.23. Persson J. The ketamine enigma. Acta Anaesthesiol Scand2008;52(4):453–5.24. Okon T. Ketamine: an introduction for the pain and palliative medicinephysician. Pain Physician 2007;10(3):493–500.25. Miller KE, Miller MM, et al. Challenges in pain management at the endof life. Am Fam Physician 2001;64(7):1227–34.26. Mercadante S, Villari P, et al. Opioid switching and burst ketamine toimprove the opioid response in patients with movement-related paindue to bone metastases. Clin J Pain 2009;25(7):648–9.27. Jensen TS, Finnerup NB. Neuropathic pain treatment: a further stepforward. Lancet 2009;374(9697):1218–9.28. Attal N. Management of neuropathic cancer pain. Ann Oncol2010;21(5):1134–5.29. Sharma S, Rajagopal MR, et al. A phase II pilot study to evaluate use ofintravenous lidocaine for opioid-refractory pain in cancer patients. JPain Symptom Manage 2009;37(1):85–93.30. Buchanan DD, JMF. A role for intravenous lidocaine in severe cancerrelatedneuropathic pain at the end-of-life. Support Care Cancer,2010.31. Bartusch SL, Sanders BJ, et al. Clonazepam for the treatment of lancinatingphantom limb pain. Clin J Pain 1996;12(1):59–62.32. Giovannoni MP, Ghelardini C, et al. Alpha2-agonists as analgesicagents. Med Res Rev 2009;29(2):339–68.33. Myers J, Chan V, et al. Intraspinal techniques for pain management incancer patients: a systematic review. Support Care Cancer2010;18(2):137–49.34. Schmidtko A, Lotsch J, et al. Ziconotide for treatment of severe chronicpain. Lancet 2010;375(9725):1569–77.35. Jackson TP, Gaeta R. Neurolytic blocks revisited. Curr Pain HeadacheRep 2008;12(1):7–13.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!